Scientists connected to Harvard Medical School have advanced a genetic-reprogramming technique designed to restore more youthful patterns of cellular activity. The experimental approach uses three transcription factors—OCT4, SOX2 and KLF4, collectively known as OSK—to help older or damaged cells recover gene-expression patterns associated with healthier tissue.
Harvard researcher David Sinclair has said that related animal experiments reversed biological-age measurements in some tissues by as much as approximately 75% within weeks, although that figure should be understood as an experimental biological marker rather than proof that an entire animal became 75% younger.
The foundation for the therapy came from research published in Nature in 2020. In that study, scientists delivered the OSK factors to retinal ganglion cells in mice. The treatment restored youthful DNA-methylation and gene-expression patterns, promoted nerve regeneration and improved vision in aged mice and mouse models of glaucoma.
Researchers reported that the cells recovered important functions without being completely returned to an embryonic state or losing their cellular identity.
The research supports the theory that aging is influenced partly by the gradual loss or disruption of epigenetic information. Epigenetic instructions help cells determine which genes should be active without changing the underlying DNA sequence itself. Under this theory, older cells may still retain a record of their youthful biological state, but they become less capable of reading and following those original instructions accurately. Partial reprogramming attempts to restore access to that information while preserving the cell’s specialized function.
In January 2026, the FDA cleared an Investigational New Drug application allowing Life Biosciences to begin human testing of ER-100, an experimental gene therapy based on controlled OSK expression.
The authorization did not mean the treatment had been approved for public use. It allowed researchers to begin a Phase 1 clinical study evaluating the treatment in people with optic-nerve disorders, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.
The first patient was dosed in June 2026. The early-stage trial is focused primarily on determining whether a single injection of ER-100 is safe and tolerable. Researchers will monitor participants for side effects while also measuring changes in visual function. The trial is not yet designed to prove that aging can be reversed throughout the human body, and it remains unknown whether the vision improvements observed in mice will translate successfully to people.
Although whole-body rejuvenation remains a long-term possibility rather than an established medical outcome, the trial represents an important transition from animal research to carefully controlled human testing. Success would provide evidence that damaged human tissue may be capable of recovering more youthful function. However, researchers must first demonstrate that partial cellular reprogramming can be controlled without causing serious immune reactions, abnormal tissue growth, loss of cellular identity or other harmful effects.
BitcoinVersus.Tech Editor’s Note:
We volunteer daily to ensure the credibility of the information on this platform is Verifiably True. If you would like to support to help further secure the integrity of our research initiatives, please donate here: 3C9o19EH5HSiwEPyCTmEKzxhNCbo2X6TTb
BitcoinVersus.tech is not a financial advisor. This media platform reports on financial subjects purely for informational purposes.
Bitcoin Versus 
Leave a comment